Bernhard Saxe - Daxor Independent Director
| DXR Stock | USD 9.75 0.01 0.10% |
Director
Mr. Bernhard Saxe, Esq., is Independent Director of Daxor Corporationration He was Director since 2008. He is a retired partner in the intellectual property practice group of Foley Lardner, LLP, and former Vice President of Patent Affairs and Corporationrationrate Secretary of Immunomedics, Inc. He is a registered patent attorney and a member of the American Intellectual Property Law Association, American Bar Association and American Chemical Society. He received his J.D. from George Washington UniversityPh.D. from Columbia University and B.A. from Johns Hopkins University in chemistry. Dr. Saxe was named one of the top 10 patent prosecuting attorneys by IP Law and Business, has authored multiple articles pertaining to patent law and given many seminars and lectures on patent law and strategy. since 2012.
| Age | 75 |
| Tenure | 12 years |
| Address | 109 Meco Lane, Oak Ridge, TN, United States, 37830 |
| Phone | 212 330 8500 |
| Web | https://www.daxor.com |
Daxor Management Efficiency
The company has Return on Asset of (0.0151) % which means that on every $100 spent on assets, it lost $0.0151. This is way below average. Daxor's management efficiency ratios could be used to measure how well Daxor manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Daxor's Return On Tangible Assets are relatively stable compared to the past year. As of 04/23/2024, Return On Assets is likely to grow to 0.01, while Return On Capital Employed is likely to drop 0.01. At this time, Daxor's Total Assets are relatively stable compared to the past year. As of 04/23/2024, Return On Tangible Assets is likely to grow to 0.01, while Non Currrent Assets Other are likely to drop (36.6 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Manu Rana | HealthEquity | 45 | |
| Barbara Mowry | National Research Corp | 70 | |
| Debra McCowan | HealthEquity | 46 | |
| Michael Shmerling | HealthStream | 62 | |
| John Nunnelly | National Research Corp | 65 | |
| Gayle Wellborn | HealthEquity | 56 | |
| Harald Arnet | National Research Corp | N/A | |
| Deborah Tate | HealthStream | 61 | |
| P Shastri | National Research Corp | 65 | |
| Ian Sacks | HealthEquity | 47 | |
| Martiny Harris | HealthStream | 59 | |
| Jeffrey McLaren | HealthStream | 51 | |
| Frank Medici | HealthEquity | 53 | |
| Savita Acharya | National Research Corp | 41 | |
| Frank Gordon | HealthStream | 55 | |
| William Stead | HealthStream | 69 | |
| Dale Polley | HealthStream | 67 | |
| Thompson Dent | HealthStream | 68 | |
| Michael Leavitt | HealthEquity | 66 | |
| Adrian Dillon | HealthEquity | 63 | |
| Frank Corvino | HealthEquity | 68 | |
Management Performance
| Return On Equity | 0.0089 | ||||
| Return On Asset | -0.0151 |
Daxor Leadership Team
Elected by the shareholders, the Daxor's board of directors comprises two types of representatives: Daxor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Daxor. The board's role is to monitor Daxor's management team and ensure that shareholders' interests are well served. Daxor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Daxor's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief CFO | ||
| James Lombard, Independent Director | ||
| Michael Feldschuh, Interim CEO, Interim President, Head of Bus. Devel. and Strategic Initiatives and Director | ||
| Joseph Feldschuh, Chairman of the Board and Presidentident | ||
| Joy Goudie, Independent Director | ||
| Jean Oertel, Senior Experience | ||
| Bernhard Saxe, Independent Director | ||
| Guido Manzo, Vice Sales | ||
| Diane Meegan, Corporate Secretary | ||
| Robert Michel, Chief Financial Officer | ||
| Henry Cremisi, Director | ||
| Kathryn Kornafel, Senior Development | ||
| Robert Willens, Independent Director | ||
| Jonathan Feldschuh, Chief Scientific Officer, Director | ||
| Martin Wolpoff, Independent Director | ||
| Edward Feuer, Director | ||
| Eric Coleman, CFO | ||
| Linda Cooper, Vice Operations |
Daxor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Daxor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0089 | ||||
| Return On Asset | -0.0151 | ||||
| Profit Margin | 1.72 % | ||||
| Operating Margin | (5.11) % | ||||
| Current Valuation | 42.93 M | ||||
| Shares Outstanding | 4.81 M | ||||
| Shares Owned By Insiders | 57.08 % | ||||
| Shares Owned By Institutions | 1.53 % | ||||
| Number Of Shares Shorted | 6.95 K | ||||
| Price To Earning | 10.77 X |
Pair Trading with Daxor
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daxor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daxor will appreciate offsetting losses from the drop in the long position's value.Moving against Daxor Stock
| 0.79 | FONR | Fonar | PairCorr |
| 0.73 | DHR | Danaher Earnings Call Today | PairCorr |
| 0.67 | EVH | Evolent Health Financial Report 1st of May 2024 | PairCorr |
| 0.66 | LNSR | LENSAR Inc | PairCorr |
| 0.62 | PROF | Profound Medical Corp Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to Daxor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daxor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daxor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daxor to buy it.
The correlation of Daxor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daxor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daxor moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Daxor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Daxor. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Daxor Stock, please use our How to Invest in Daxor guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Daxor Stock analysis
When running Daxor's price analysis, check to measure Daxor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daxor is operating at the current time. Most of Daxor's value examination focuses on studying past and present price action to predict the probability of Daxor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daxor's price. Additionally, you may evaluate how the addition of Daxor to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Daxor's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Daxor. If investors know Daxor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Daxor listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.14 | Revenue Per Share 0.034 | Quarterly Revenue Growth (0.14) | Return On Assets (0.02) |
The market value of Daxor is measured differently than its book value, which is the value of Daxor that is recorded on the company's balance sheet. Investors also form their own opinion of Daxor's value that differs from its market value or its book value, called intrinsic value, which is Daxor's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Daxor's market value can be influenced by many factors that don't directly affect Daxor's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Daxor's value and its price as these two are different measures arrived at by different means. Investors typically determine if Daxor is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Daxor's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.